Sign in
4

Changes in Ownership

PTC THERAPEUTICS, INC. Filed Acc 0001415889-23-006694

EXEC. VP AND CLO sold 61,923 shares at an average $51.42 ($3,183,830)

  • EXEC. VP AND CLO acquired 61,923 shares (option exercise)
  • Traded under a Rule 10b5-1 plan

From the SEC's structured data for this filing

Trades in this filing

Table I: Non-derivative

Insider Date Transaction Shares Price Value Owned after D/I
Boulding Mark Elliott EXEC. VP AND CLO 2023-04-17 Option exercise 10b5-1 +3,292 $30.86 $101,591 78,670 D: show line 1 in the form
Boulding Mark Elliott EXEC. VP AND CLO 2023-04-17 Sale 10b5-1 −3,292 $51.42 $169,276 75,378 D: show line 2 in the form
Boulding Mark Elliott EXEC. VP AND CLO 2023-04-17 Option exercise 10b5-1 +58,631 $30.86 $1,809,353 134,009 D: show line 3 in the form
Boulding Mark Elliott EXEC. VP AND CLO 2023-04-17 Sale 10b5-1 −58,631 $51.42 $3,014,554 75,378 D: show line 4 in the form
Open-market sales · 61,923 sh · avg $51.42 · $3,183,830

Table II: Derivative

Insider Date Transaction Shares Price Value Owned after D/I
Boulding Mark Elliott EXEC. VP AND CLO 2023-04-17 Option exercise · Stock Option (Right to Buy) 10b5-1 −3,292 $30.86 $101,591 58,631 D: show line 5 in the form
Boulding Mark Elliott EXEC. VP AND CLO 2023-04-17 Option exercise · Stock Option (Right to Buy) 10b5-1 −58,631 $30.86 $1,809,353 0 D: show line 6 in the form
Loading xslF345X04/form4-04192023_080455.xml…